Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 combination with radiotherapy and bevacizumabSurvival rate in this cohort at 19 months is 10-fold greater than a reference cohort of matched patients receiving standard of care (50% vs. 5%)BERLIN (BUSINES.
TME Pharma Announces Results of Successful Capital Increase With Preferential Subscription Rights for €2 7 Million streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
TME Pharma N V : TME Pharma Announces Results of Successful Capital Increase With Preferential Subscription Rights for €2 7 Million finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
This information is not intended for residents of the United Kingdom, United States, Australia, Canada or Japan. See Annex for full disclaimer. TME PHARMA.
TME Pharma Launches Fully Guaranteed €2 7 Million Preferential Rights Issue With Warrants Attached Combined With Buyback of Convertible Debt finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.